New CAR-T therapy targets Hard-to-Treat blood cancer
NCT ID NCT07195617
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 26 times
Summary
This early study tests a new type of CAR-T cell therapy (BCMA-GPRC5D) in 10 adults with relapsed/refractory multiple myeloma who have already tried at least three prior treatments. The therapy uses the patient's own immune cells, modified to attack two cancer targets, and is given as a single infusion. The main goals are to check safety and see if the treatment can control the cancer. Because multiple myeloma often requires ongoing management, this is not expected to be a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.